17R Analyst Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
17R Stock 12 Month Forecast
Average Price Target
―| Highest Price TargetCHF74.21 | Average Price TargetCHF62.59 | Lowest Price TargetCHF51.12 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Piper Sandler
CHF56.07
Buy
―
Reiterated
10/21/26
Wells Fargo
CHF65.96
Buy
―
Reiterated
10/15/26
Guggenheim
CHF73.38
Buy
―
Reiterated
10/06/26
H.C. Wainwright
CHF55.24
Buy
―
Reiterated
10/02/26
Bank of America Securities
CHF58.54
Buy
―
Reiterated
09/23/26
Wedbush
CHF61.84→CHF62.66
Buy
―
Reiterated
09/22/26
Canaccord Genuity
CHF57.72
Buy
―
Reiterated
08/11/26
Evercore ISI
CHF56.07→CHF64.31
Buy
―
Reiterated
08/10/26
Stifel Nicolaus
CHF35.45→CHF51.12
Hold
―
Reiterated
08/09/26
J.P. Morgan
CHF43.7→CHF74.21
Buy
―
Reiterated
08/06/26
Citi
CHF57.72→CHF70.08
Buy
―
Reiterated
08/06/26
TD Cowen
CHF49.47→CHF61.84
Buy
―
Reiterated
08/04/26
Cantor Fitzgerald
―
Buy
―
Reiterated
02/20/26
Leerink Partners
―
Buy
―
Reiterated
01/13/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
CHF56.07
Buy
―
Reiterated
10/21/26
Wells Fargo
CHF65.96
Buy
―
Reiterated
10/15/26
Guggenheim
CHF73.38
Buy
―
Reiterated
10/06/26
H.C. Wainwright
CHF55.24
Buy
―
Reiterated
10/02/26
Bank of America Securities
CHF58.54
Buy
―
Reiterated
09/23/26
Wedbush
CHF61.84→CHF62.66
Buy
―
Reiterated
09/22/26
Canaccord Genuity
CHF57.72
Buy
―
Reiterated
08/11/26
Evercore ISI
CHF56.07→CHF64.31
Buy
―
Reiterated
08/10/26
Stifel Nicolaus
CHF35.45→CHF51.12
Hold
―
Reiterated
08/09/26
J.P. Morgan
CHF43.7→CHF74.21
Buy
―
Reiterated
08/06/26
Citi
CHF57.72→CHF70.08
Buy
―
Reiterated
08/06/26
TD Cowen
CHF49.47→CHF61.84
Buy
―
Reiterated
08/04/26
Cantor Fitzgerald
―
Buy
―
Reiterated
02/20/26
Leerink Partners
―
Buy
―
Reiterated
01/13/26
Best Analysts Covering Travere Therapeutics
3 Months
Success Rate
14/21 ratings generated profit
Average Return
+26.08%
Copying Jason Zemansky's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +26.08% per trade.
1 Year
Success Rate
18/21 ratings generated profit
Average Return
+80.22%
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +80.22% per trade.
2 Years
Success Rate
18/21 ratings generated profit
Average Return
+165.28%
Copying Jason Zemansky's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +165.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
17R Analyst Recommendation Trends
Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
1
0
0
0
2
Buy
42
34
33
23
19
Hold
2
1
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
35
35
25
23
Each month's total comprises the sum of three months' worth of ratings.
17R Financial Forecast
17R Stock Forecast FAQ
What is CH:17R’s average 12-month price target, according to analysts?
Based on analyst ratings, Travere Therapeutics’s 12-month average price target is 62.59.
What is CH:17R’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:17R, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Travere Therapeutics a Buy, Sell or Hold?
Travere Therapeutics has a consensus rating of Strong Buy, which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
What is Travere Therapeutics’s share price target?
The average share price target for Travere Therapeutics is 62.59. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF74.21 ,and the lowest forecast is CHF51.12. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is CHF74.21 ,and the lowest forecast is CHF51.12. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about Travere Therapeutics?
Travere Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of Travere Therapeutics?
To buy shares of CH:17R, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.